JP2006514991A5 - - Google Patents

Download PDF

Info

Publication number
JP2006514991A5
JP2006514991A5 JP2005509699A JP2005509699A JP2006514991A5 JP 2006514991 A5 JP2006514991 A5 JP 2006514991A5 JP 2005509699 A JP2005509699 A JP 2005509699A JP 2005509699 A JP2005509699 A JP 2005509699A JP 2006514991 A5 JP2006514991 A5 JP 2006514991A5
Authority
JP
Japan
Prior art keywords
retinoic acid
compound
cis
cra
general formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2005509699A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006514991A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2003/014071 external-priority patent/WO2004058234A2/en
Publication of JP2006514991A publication Critical patent/JP2006514991A/ja
Publication of JP2006514991A5 publication Critical patent/JP2006514991A5/ja
Pending legal-status Critical Current

Links

JP2005509699A 2002-12-27 2003-12-11 新規医薬組合せ Pending JP2006514991A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP02090431 2002-12-27
EP03090061 2003-03-12
PCT/EP2003/014071 WO2004058234A2 (en) 2002-12-27 2003-12-11 Pharmaceutical combinations of phthalazine vegf inhibitors and benzamide hdac inhibitors

Publications (2)

Publication Number Publication Date
JP2006514991A JP2006514991A (ja) 2006-05-18
JP2006514991A5 true JP2006514991A5 (https=) 2006-12-07

Family

ID=32683819

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2005509699A Pending JP2006514991A (ja) 2002-12-27 2003-12-11 新規医薬組合せ

Country Status (4)

Country Link
EP (2) EP1738752A1 (https=)
JP (1) JP2006514991A (https=)
AU (1) AU2003292888A1 (https=)
WO (1) WO2004058234A2 (https=)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6897220B2 (en) 2001-09-14 2005-05-24 Methylgene, Inc. Inhibitors of histone deacetylase
CN101851173A (zh) 2001-09-14 2010-10-06 梅特希尔基因公司 组蛋白脱乙酰化酶抑制剂
US7868204B2 (en) 2001-09-14 2011-01-11 Methylgene Inc. Inhibitors of histone deacetylase
EP1641759B1 (en) * 2003-07-07 2014-03-12 Merck Patent GmbH Malonamide derivatives
WO2005030705A1 (en) 2003-09-24 2005-04-07 Methylgene, Inc. Inhibitors of histone deacetylase
US7253204B2 (en) 2004-03-26 2007-08-07 Methylgene Inc. Inhibitors of histone deacetylase
SE0401790D0 (sv) * 2004-07-07 2004-07-07 Forskarpatent I Syd Ab Tamoxifen response in pre- and postmenopausal breast cancer patients
EP1824831A2 (en) * 2004-12-16 2007-08-29 Takeda San Diego, Inc. Histone deacetylase inhibitors
CN101163690A (zh) 2005-04-20 2008-04-16 默克公司 苯并噻吩异羟肟酸衍生物
EP1874294A4 (en) 2005-04-20 2010-12-01 Merck Sharp & Dohme BENZOTHIOPHENO HYDROXAMIDIC DERIVATIVES WITH CARBAMATE, UREA, AMID AND SULPHONAMIDE SUBSTITUTIONS
CA2605110A1 (en) 2005-04-20 2006-11-02 Merck & Co., Inc. Benzothiophene derivatives
EP1896436A2 (en) 2005-05-11 2008-03-12 Takeda San Diego, Inc. Histone deacetylase inhibitors
CA2612420A1 (en) 2005-06-24 2007-01-04 Merck & Co., Inc. Modified malonate derivatives
EA200800321A1 (ru) 2005-07-14 2008-06-30 Такеда Сан Диего, Инк. Ингибиторы гистондеацетилазы
AR057579A1 (es) 2005-11-23 2007-12-05 Merck & Co Inc Compuestos espirociclicos como inhibidores de histona de acetilasa (hdac)
JP2009120486A (ja) * 2005-12-05 2009-06-04 Mitsubishi Pharma Corp 核内オーファン受容体の新規活性化剤及びその用途
WO2007100657A2 (en) 2006-02-28 2007-09-07 Merck & Co., Inc. Inhibitors of histone deacetylase
CN101466670B (zh) 2006-04-07 2013-04-17 梅特希尔基因公司 组蛋白脱乙酰酶抑制剂
CA2649861A1 (en) 2006-04-26 2007-11-08 Merck & Co., Inc. Disubstituted aniline compounds
EP2023924B1 (en) 2006-05-18 2016-08-03 Merck Sharp & Dohme Corp. Aryl-fused spirocyclic compounds
EP2049124A4 (en) 2006-07-20 2010-02-10 Merck & Co Inc PHOSPHOR DERIVATIVES AS HISTONDEACETYLASE HEMMER
AU2008269154B2 (en) 2007-06-27 2014-06-12 Merck Sharp & Dohme Llc 4-carboxybenzylamino derivatives as histone deacetylase inhibitors
EP2170339B1 (en) 2007-06-27 2014-10-15 Merck Sharp & Dohme Corp. Pyridyl and pyrimidinyl derivatives as histone deacetylase inhibitors
EP2060565A1 (en) 2007-11-16 2009-05-20 4Sc Ag Novel bifunctional compounds which inhibit protein kinases and histone deacetylases
AU2009289649B2 (en) 2008-09-03 2016-05-05 Biomarin Pharmaceutical Inc. Compositions including 6-aminohexanoic acid derivatives as HDAC inhibitors
EP2429987A4 (en) * 2009-05-15 2012-10-03 Korea Res Inst Chem Tech AMIDE COMPOUND, PROCESS FOR PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME
US8912184B1 (en) 2010-03-01 2014-12-16 Alzheimer's Institute Of America, Inc. Therapeutic and diagnostic methods
US8957066B2 (en) 2011-02-28 2015-02-17 Biomarin Pharmaceutical Inc. Histone deacetylase inhibitors
US9540395B2 (en) 2011-02-28 2017-01-10 Biomarin Pharmaceutical Inc. Histone deacetylase inhibitors
US10059723B2 (en) 2011-02-28 2018-08-28 Biomarin Pharmaceutical Inc. Histone deacetylase inhibitors
WO2014160221A1 (en) 2013-03-13 2014-10-02 The General Hospital Corporation Photoswitchable hdac inhibitors
DK2970139T3 (en) 2013-03-15 2018-08-13 Biomarin Pharm Inc HDAC inhibitors
TWI635077B (zh) * 2016-08-11 2018-09-11 行政院原子能委員會核能研究所 針對腫瘤診斷與治療之組織蛋白去乙醯酶抑制劑(HDACi)PET造影化合物與類似物,及其製造方法
US11208382B2 (en) * 2017-07-28 2021-12-28 Hangzhou Solipharma Co., Ltd. Entinostat-containing compound, crystal form of compound thereof, and preparation method therefor and pharmaceutical composition thereof
US12522587B2 (en) 2018-05-04 2026-01-13 Remedy Plan, Inc. Cancer treatments targeting cancer stem cells
CA3143188A1 (en) * 2019-06-13 2020-12-17 Dana-Farber Cancer Institute, Inc. Hdac3 catalytic inhibitor development and uses thereof
EP4055008A1 (en) 2019-11-06 2022-09-14 Remedy Plan, Inc. Cancer treatments targeting cancer stem cells
HRP20251279T1 (hr) 2020-04-30 2025-12-05 Great Novel Therapeutics Biotech & Medicals Corporation Inhibitori histon deacetilaze za imunomodulaciju u tumorskom mikrookruženju
CN114957132A (zh) * 2021-02-20 2022-08-30 中国科学院上海药物研究所 含s构型的氨基苯甲酰胺基哒嗪酮类化合物、其制备方法、药物组合物及应用
CN113200908B (zh) * 2021-04-09 2022-07-19 南华大学 一种含叔胺的邻氨基苯甲酰胺类化合物及其制备与应用
CN115703736B (zh) * 2021-08-04 2025-05-16 中国海洋大学 靶向于hdac和nad合成的多靶点抑制剂及其用途
KR102743956B1 (ko) * 2021-10-08 2024-12-17 아주대학교산학협력단 히스톤 탈아세틸화효소 억제제를 포함하는 대사성 질환의 예방, 개선 또는 치료용 조성물

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2097788B (en) 1981-04-03 1985-04-24 Lilly Co Eli Benzothiophene compounds and process for preparing them
DE3121152A1 (de) 1981-05-22 1982-12-09 Schering Ag, 1000 Berlin Und 4619 Bergkamen "verwendung der kombination eines aromatase-hemmers mit einem antiandrogen zur prophylaxe und therapie der prostatahyperplasie"
US5053405A (en) 1990-06-21 1991-10-01 Sterling Drug Inc. Antiandrogenic sulfonylsteroidothiazoles
SE9300971D0 (sv) * 1993-03-24 1993-03-24 Jan Wadstein Hudvaardskomposition
US6174905B1 (en) 1996-09-30 2001-01-16 Mitsui Chemicals, Inc. Cell differentiation inducer
CO4950519A1 (es) * 1997-02-13 2000-09-01 Novartis Ag Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion
GB0111078D0 (en) * 2001-05-04 2001-06-27 Novartis Ag Organic compounds
PL367349A1 (en) * 2001-09-12 2005-02-21 Novartis Ag Use of 4-pyridylmethylphthalazines for cancer treatment
US20040266779A1 (en) * 2001-09-27 2004-12-30 Anderson Kenneth C. Use of c-kit inhibitors for the treatment of myeloma
WO2003059354A2 (en) * 2001-12-21 2003-07-24 Bayer Pharmaceuticals Corporation Anti-angiogenesis combination therapies comprising pyridazine or pyridine derivatives

Similar Documents

Publication Publication Date Title
JP2006514991A5 (https=)
US10882835B2 (en) KDM1A inhibitors for the treatment of disease
RU2342367C2 (ru) Ненуклеозидные ингибиторы i обратной транскриптазы, предназначенные для лечения заболеваний, опосредованных вич
WO2014164867A1 (en) Kdm1a inhibitors for the treatment of disease
JP2006526590A5 (https=)
EP2269609A3 (en) Treatment of neurodegenerative diseases and cancer of the brain with SAHA
HUP0104666A2 (hu) Új tiroid receptor ligandumok és II-es módszer
JP2009511508A5 (https=)
WO1998047505A9 (en) Neuropeptide y receptor antagonist
JP2004534850A5 (https=)
CA2379841A1 (en) Biphenyl derivatives, the preparation thereof and their use as medicaments
TNSN03084A1 (en) Anthranilic acid amides, method for the production thereof, their use as antiarrhythmia agents, and pharmaceutical preparations thereof
PT1506185E (pt) Compostos novos e sua utilizacao
EP1251126A3 (en) Fluoro-substituted benzenesulfonyl compounds for the treatment of inflammation
AU3850600A (en) Dalda analogs and their use
CN113939514A (zh) 吡咯并嘧啶类化合物及其应用
EP2308828A3 (en) CaSR antagonist
BRPI0610644B8 (pt) composto e composição farmacêutica que compreende tal composto e um veículo ou diluente farmaceuticamente aceitável.
JP2026040489A (ja) 骨髄増殖性新生物の治療のためのリシン特異的ヒストンデメチラーゼ阻害剤
WO2001030749B1 (en) Novel compounds
JP2022028975A5 (https=)
CA2388759A1 (en) Substituted piperazine derivatives, the preparation thereof and their use as medicaments
TW200500061A (en) New pharmaceutical compositions containing ambroxol and isopropamide iodide
CA2392630A1 (en) 2-amino-5,6-dihalo-3,4-dihydroquinazolines with blood platelet reducing properties
RU2001116601A (ru) Новые производные пиримидина и способы их получения